The Dutch biotech has signed off a sizeable series B fundraising to take its intranasal products to fight current and future viral outbreaks into the clinic.

Biocon anticipates significant US uptake of its Viatris-partnered interchangeable insulin glargine biosimilar on the back of commercial arrangements in place and expects to "move the market" in 2022.  All eyes are also on the trajectory of biosimilar insulin aspart, which received a CRL from the US FDA.

The US FDA issued a complete response letter for the P2X3 receptor antagonist for the treatment of refractory chronic cough, requesting more efficacy data.

While chasing Amgen’s Lumakras in NSCLC, Mirati looks to now have an edge in two other tumor types.

When almost everything that could go wrong has gone wrong at a company, the proposition of it turning acquirer may meet with some resistance from its proposed targets and their investors.

Lupin’s partnership with Shenzhen Foncoo marks the Indian firm's much-awaited entry into China. Will this and more planned alliances make Lupin a worthy respiratory challenger to AstraZeneca, compatriot Cipla and others in a country where chronic respiratory diseases are the second leading cause of death?

The bosses of Bayer and Roche's pharmaceutical divisions – Stefan Oelrich and Bill Anderson – have called on governments in Europe to create a friendlier environment so that the sector and policymakers can continue to work better together post-pandemic.

The arrival on the US eczema market of a couple of oral JAK inhibitors with stellar data on itching could provide a challenge to Sanofi and Regeneron's blockbuster Dupixent. However, Pfizer and AbbVie will have to overcome dermatologists' fears about the class-effect safety warnings their drugs come with.

Scrip's Kevin Grogan joins Datamonitor's Pamela Spicer and Davinderpreet Mangat to discuss the skin disease landscape and whether atopic dermatitis is now where psoriasis was a decade ago as another wave of innovative products start to reach the market.

The Cambridge, MA start-up aims to ‘democratize’ therapies based on induced pluripotent stem cells by developing an automated manufacturing system.

The company published data for the bispecific antibody in wet AMD and DME, with non-inferior efficacy to Eylea and growing support for less frequent administration.

The French major has committed up to £5m for non-profit Protas, which aims to facilitate large clinical studies at a fraction of the usual price and form more pharmaceutical collaborations down the line.